Phase II Trial Begins for Potential Alzheimer’s Drug

A phase II safety trial to investigate a potential new treatment for Alzheimer’s has begun. MSD, known as Merck & Co Inc, will trial a drug called MK-8931 in people with mild to moderate stage Alzheimer’s disease. MK-8931 aims to block an enzyme called BACE, which is known to play … Continue reading